Informed treatment procedure within Chimeric Antigen Receptor-T Cell Therapy – from a user perspective, phase 1
This study is a doctoral project in collaboration with Karolinska that aims to investigate patients' and healthcare professionals' experiences of CAR-T cell therapy, with a specific focus on the need for information, communication, problems, symptoms and support.
Start
2025-03-01
Planned completion
2026-06-01
Main financing
Collaboration partners
Research group
Project manager at MDU
External project members
Sólveig Adalsteinsdóttir, Head of nurse development for cell therapy at Karolinska University Hospital and a PhD student.
Jeanette Winterling, Associate Professor in Nursing at Karolinska University Hospital.
About the project
There is an unexplored area when it comes to patients' and healthcare professionals' experiences of cancer treatments and this project will investigate Chimeric Antigen Receptor-T (CAR-T) cell therapy with a focus on information and communication. This project aims to investigate patients' and healthcare professionals' experiences of CAR-T cell therapy. CAR-T cell therapy is an advanced and groundbreaking treatment for certain types of cancer and it involves the patient's own T cells being genetically modified to specifically attack and kill cancer cells. This treatment has proven effective against cancers that were previously difficult to treat but it also involves complex treatment courses and demanding aftercare.
Project objective
The study consists of two sub-studies. Sub-study 1 aims to provide a description of how patients experience CAR-T cell therapy regarding information, communication, problems, symptoms and support before, during and after treatment. Sub-study 2 aims to provide a description of healthcare professionals' perspectives on patients' experiences of information, communication, problems, symptoms and support.
